Silo Pharma Secures Patent for Innovative PTSD Treatment
Silo Pharma, Inc. (NASDAQ: SILO), a biopharmaceutical marvel with a focus on groundbreaking therapies for psychiatric and neurological disorders, has recently received a promising Notice of Allowance from the U.S. Patent and Trademark Office (USPTO). This notice pertains to their pharmacological treatment aimed at preventing stress-related disorders, particularly in women. The company's robust market performance has been noteworthy, showcasing impressive gross profit margins, indicative of its rising position in the competitive pharmaceutical sector.
Strengthening Intellectual Property Portfolio
The newly allowed patent application, number 17/954,864, is relevant to Silo's ongoing momentum with its primary product, SPC-15, a serotonin 5-HT4 receptor agonist focused on treating conditions such as PTSD and anxiety. This patent is an essential step in bolstering Silo Pharma’s intellectual property, further enhancing its technological rights and business strategy as they expand on previously established claims. Notably, the company received significant recognition with U.S. Patent 11,491,120 back in early 2023, which laid the groundwork for their current advancements.
A View from Leadership
Eric Weisblum, the CEO of Silo, expressed a positive outlook regarding this patent issuance. He conveyed that the new patent would significantly strengthen Silo Pharma's portfolio, granting additional safeguards to their valuable technologies. Importantly, Silo has an exclusive licensing deal with Columbia University, enabling global development, manufacture, and commercialization of SPC-15. This collaboration brings with it a comprehensive array of both issued patents and pending applications, signaling a strong foundation for future advancements.
FDA Approval and Research Development
SPC-15 may have the chance to navigate the FDA approval maze more swiftly, thanks to the advantageous 505(b)(2) regulatory pathway tied to its intranasal delivery system. Currently, Silo Pharma is engaged in collaborative preclinical studies with Columbia University while maintaining exclusive rights to develop and market this innovative treatment.
Exploring Expanded Therapeutics
Beyond SPC-15, Silo Pharma has set its sights on other promising preclinical programs. These include SP-26, an innovative time-release ketamine-loaded implant aimed at providing relief for fibromyalgia and chronic pain, alongside SPC-14, targeted for Alzheimer’s disease, and SPU-16, a CNS-homing peptide that aims to address multiple sclerosis (MS). Each of these endeavors reinforces the company’s commitment to finding solutions for challenging health conditions.
Recent Progress and Financial Developments
In the latest updates, Silo Pharma has recorded substantial progress with its PTSD treatment and the advancement of its ketamine implant for chronic pain management. The company has successfully completed a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding SPC-15, anticipating the submission of an Investigational New Drug (IND) application in the near future. Furthermore, Silo has secured an exclusive global license from Columbia University, solidifying its foundation for SPC-15's development and commercialization.
Ahead of early 2025, preparations are underway for animal studies associated with SP-26, aimed at providing consistent pain relief. Financially, Silo Pharma has bolstered its capital through a remarkable $2.1 million raised via a registered direct offering and a concurrent private placement of securities, with these funds earmarked for working capital and organizational needs. Recently, during the annual shareholders' meeting, the company celebrated the re-election of its board members and the endorsement of its independent accounting firm, Salberg & Company, P.A.
Commitment to Innovation
These strides emphasize Silo Pharma's fervent commitment to advancing the pharmaceutical landscape and addressing overlooked conditions like stress-induced psychiatric disorders and chronic pain. The innovative nature of their work not only offers hope to those affected but also positions Silo Pharma as a significant player in the evolving field of therapeutic pharmaceuticals.
Frequently Asked Questions
What major development did Silo Pharma announce recently?
Silo Pharma announced the receipt of a Notice of Allowance for a patent related to its PTSD treatment, SPC-15.
How does SPC-15 work?
SPC-15 operates as a serotonin 5-HT4 receptor agonist, targeting stress-induced conditions like PTSD and anxiety.
What future steps is Silo Pharma planning for SPC-15?
The company aims to submit an IND application to the FDA in the near future, following positive pre-IND meeting feedback.
What other programs is Silo Pharma developing?
Besides SPC-15, Silo is working on SP-26 for chronic pain, SPC-14 for Alzheimer’s, and SPU-16 targeting multiple sclerosis.
How much funding did Silo Pharma recently acquire?
Silo Pharma raised approximately $2.1 million through a registered direct offering, which is intended for working capital and corporate expenses.
